Press Release - 28 November 2022 SSIA SAW A STRONG RECOVERY IN CONSTRUCTION AND HOSPITALITY BUSINESS SEGMENT IN 9M22, NET PROFIT INCREASED BY 126% YoY . | November 28, 2022
Circle Pharma Raises $66M in Series C Financing
Circle Pharma, Inc., a South San Francisco, Calif.-based macrocycle drug discovery and development company focused on intractable cancer targets, raised $66m in Series C financing.
The round was co-led by The Column Group and Nextech Invest with participation from Pandect Bioventures, together with new investors including Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment and Eli Lilly and Company.
The company intends to use the funds to advance its wholly owned cyclin-targeted programs towards the clinic, with potential applications in Rb-dysregulated cancers such as small cell lung cancer and cyclin E dependent malignancies, including ovarian cancer. In addition, Circle Pharma will apply its macrocycle platform to other precision oncology targets that have a clear therapeutic rationale but are considered undruggable with small molecules.